Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2005 1
2007 3
2008 1
2009 1
2010 3
2011 3
2012 6
2013 5
2014 3
2015 4
2016 3
2017 7
2018 5
2019 4
2020 7
2021 6
2022 1
2023 9
2024 1
2025 9
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease.
Bellver-Sanchis A, Valle-Garcia D, Barbaraci C, Romero-Becerra F, Singh RK, Jarne-Ferrer J, Vasilopoulou F, Irisarri A, Martínez-Fernández C, Fafián-Labora JA, Arufe MC, Wüst C, Castellanos A, Soto D, Casals N, Fadó R, Pocock JM, Navarro G, Val C, Brea J, Loza MI, Lleó A, Fortea J, Alcolea D, Perez-Bosque A, Miró L, Pérez B, Rashid S, Ali M, Saqib M, Lí Carbó M, Guerrero A, Vázquez S, Choudhary BS, Dai S, Escolano C, Franco R, Pallàs M, Griñán-Ferré C. Bellver-Sanchis A, et al. Among authors: casals n. Mol Ther. 2026 Apr 1;34(4):2372-2407. doi: 10.1016/j.ymthe.2025.12.038. Epub 2025 Dec 24. Mol Ther. 2026. PMID: 41445192 Free article.
Beta-hydroxybutyrate counteracts the deleterious effects of a saturated high-fat diet on synaptic AMPAR receptors and cognitive performance.
Rojas R, Griñán-Ferré C, Castellanos A, Griego E, Martínez M, de Dios Navarro-López J, Jiménez-Díaz L, Rodríguez-Álvarez J, Soto Del Cerro D, Castillo PE, Pallàs M, Casals N, Fadó R. Rojas R, et al. Among authors: casals n. Mol Metab. 2025 Sep;99:102207. doi: 10.1016/j.molmet.2025.102207. Epub 2025 Jul 6. Mol Metab. 2025. PMID: 40628351 Free PMC article.
An overview of nanomedicines for neuron targeting.
Garcia-Chica J, D Paraiso WK, Tanabe S, Serra D, Herrero L, Casals N, Garcia J, Ariza X, Quader S, Rodriguez-Rodriguez R. Garcia-Chica J, et al. Among authors: casals n. Nanomedicine (Lond). 2020 Jul;15(16):1617-1636. doi: 10.2217/nnm-2020-0088. Epub 2020 Jul 3. Nanomedicine (Lond). 2020. PMID: 32618490 Review.
Drug uptake-based chemoresistance in breast cancer treatment.
Muley H, Fadó R, Rodríguez-Rodríguez R, Casals N. Muley H, et al. Among authors: casals n. Biochem Pharmacol. 2020 Jul;177:113959. doi: 10.1016/j.bcp.2020.113959. Epub 2020 Apr 7. Biochem Pharmacol. 2020. PMID: 32272110 Free article. Review.
Molecular genetics of HMG-CoA lyase deficiency.
Pié J, López-Viñas E, Puisac B, Menao S, Pié A, Casale C, Ramos FJ, Hegardt FG, Gómez-Puertas P, Casals N. Pié J, et al. Among authors: casals n. Mol Genet Metab. 2007 Nov;92(3):198-209. doi: 10.1016/j.ymgme.2007.06.020. Epub 2007 Aug 9. Mol Genet Metab. 2007. PMID: 17692550 Review.
80 results